Editorial: Adaptive immune resistance in cancer therapy.

Jiang, Aimin; Chen, Ouyang; Liu, Zhigang; Cai, Hongzhou; Wang, Linhui; Qi, Lin

Jiang, Aimin; Chen, Ouyang; Liu, Zhigang; Cai, Hongzhou; Wang, Linhui; Qi, Lin.

Afiliación

Jiang A; Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
Chen O; Department of Cell Biology, Duke University Medical Center, Durham, NC, United States.
Liu Z; Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Dongguan, Guangdong, China.
Cai H; Department of Urology, Jiangsu Cancer Hospital and The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
Wang L; Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
Qi L; Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Front Pharmacol ; 14: 1277902, 2023.

Article en En | MEDLINE | ID: mdl-37693895

Palabras clave

adaptive immune resistance; biomarker; immunotherapy; prognosis; tumour microenvironment (TME)

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google